The Permanente Medical Group, Inc.’s Post

The Food and Drug Administration approved the first two treatments for tricuspid regurgitation—a breakthrough in cardiology that offers hope to patients who until now have had few if any therapeutic options. Kaiser Permanente San Francisco Medical Center’s Andrew Rassi, M.D., spoke with Cardiovascular Business about these approvals and what they mean for patients and physicians. #HealthCareInnovation #Cardiology #HeartHealth https://lnkd.in/gb8iVxMk

Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

cardiovascularbusiness.com

To view or add a comment, sign in

Explore topics